Revolution Medicines Announces Issuance of U.S. Patent Covering Compositions of Matter for its Clinical-Stage SHP2 Inhibitor Program
Revolution Medicines, Inc. (RVMD)
Company Research
Source: GlobeNewswire
REDWOOD CITY, Calif., March 18, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 10,590,090 providing, in part, composition of matter protection for its SHP2 inhibitors, including RMC-4630. RMC-4630, the company’s investigational SHP2 inhibitor, is a potent and orally bioavailable small molecule that is designed to selectively inhibit the activity of SHP2, an upstream cellular protein that plays a central role in modulating cell survival and growth by transmitting signals from receptor tyrosine kinases to RAS. “We have systematically built our SHP2 program intellectual property portfolio while advancing RMC-4630 in a multi-cohort Phase 1/2 clinical program. This patent reflects innovative work and provides important coverage for our SHP2 program compounds,
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- One Revolution Medicines Insider Raised Their Stake In The Previous Year [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswire
- Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at HC Wainwright from $64.00 to $72.00. They now have a "buy" rating on the stock.MarketBeat
- Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswire
RVMD
Earnings
- 11/6/24 - Miss
RVMD
Sec Filings
- 12/20/24 - Form 4
- 12/18/24 - Form 4
- 12/18/24 - Form 4
- RVMD's page on the SEC website